immune metabolic News
-
Bisphenol A: EFSA consults on assessment of risks to human health
EFSA is launching a public consultation on its draft assessment of the human health risks posed by exposure to bisphenol A (BPA). The Authority has undertaken a comprehensive review of scientific literature and previous risk assessments from expert bodies on BPA. All stakeholders and interested parties are invited to comment on the document through an online public consultation that runs until ...
-
New Study: Infant Gut Health Must Focus on Microbiome Function, Not Diversity
The concepts of ecology, conservation, and restoration typically conjure images of natural woodlands, water systems and air quality. However, a new peer-reviewed perspective by Evolve BioSystems is taking a page from ecology playbooks in an effort to assist neonatologists and other pediatric health care professionals in assessing the state of the infant gut microbiome, which plays a significant ...
-
Fosun Pharma and Neovii signed an agreement to exclusively sell and develop Grafalon (anti-human T cell rabbit immunoglobulin) in China
Shanghai, China and Rapperswil, Switzerland) Shanghai Fosun Pharma (Group) Co. (“Fosun Pharma”, stock code : 600196.SH; 02196.HK) announced that Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (“Fosun Pharmaceutical Industry”), a controlled subsidiary, signed an exclusive sales agency and development agreement with Switzerland ’s Neovii Pharmaceuticals ...
-
Increase in cancers and fertility problems may be caused by household chemicals and pharmaceuticals
Chemicals which disrupt the hormone system – also known as 'endocrine disrupting chemicals' (EDCs) – may be a contributing factor behind the significant increases in cancers, diabetes and obesity, falling fertility, and an increased number of neurological development problems in both humans and animals, according to a review of recent scientific literature commissioned by the European ...
-
Regor Therapeutics Announces Completion of $90 Million Series B Financing
Regor Therapeutics, a clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders and metabolic diseases, announces the successful completion of $90 million Series B financing. Founded in July of 2018 by a group of veteran drug hunters with extensive research and executive leadership experiences at top multinational pharmaceutical ...
-
Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660
Rebiotix and Ferring are the first to announce positive preliminary results on primary efficacy endpoint from ongoing pivotal Phase 3 clinical trial for RBX2660 RBX2660 is an investigational, non-antibiotic, microbiome-based therapy, developed to reduce Clostridioides difficile (C. diff) infection recurrences CDC defines C. diff as a major burden to patients and doctors and an urgent ...
-
CD BioSciences Introduces mTOR Pathway for Metabolism Research
CD BioSciences, a US-based life science research product supplier and CRO, recently launches mTOR Pathway to the life science community for research applications. These new signaling pathways and other metabolic signaling pathways, such as Insulin Signaling Pathway and AMPK pathway, will support researchers in all aspects of cell death study. A metabolic pathway is a series of metabolic chemical ...
-
Symberix Awarded Multiple SBIR Grants from National Institutes of Health to Develop Proprietary Microbiome-Targeted Drugs
Symberix, a leader in the discovery of drugs that selectively target the human microbiome, announced today that it has been awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH). These grants will fund the research of new drugs that safely and selectively inhibit a bacterial enzyme responsible for a number of dose-limiting gastrointestinal (GI) ...
-
LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022
LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented new drugs based on innovative technologies, today announced that a new drug candidate for NASH was selected for an oral presentation at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting 2022, to be held November 4-8 in Washington DC. As part of the presentation, LISCure ...
-
Symberix Adds Pharmaceutical Industry Executive to Board of Directors, Expands Key Patent Asset and Joins Blackstone Entrepreneurs Network
Symberix, a pioneer in microbiome-targeted drug discovery, announced today the addition of P. Kay Wagoner, Ph.D. to its Board of Directors, the allowance of broad method-of-treatment claims for an invention licensed to Symberix by University of North Carolina and inclusion as a Portfolio Company in the Blackstone Entrepreneurs Network, a resource for high potential start-up companies. Dr. ...
-
Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment Outcomes
Study shows benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancers 54% of patients demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared to previous therapy 40% of patients experienced exceptional responses lasting at least three ...
By Exscientia
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you